1. In a long-term follow-up study of an earlier randomized control trial, participants demonstrated sustained immunity 10 years after receiving a 3-dose series of human papilloma virus (HPV) vaccination. 2. There were no HPV-related malignancies or vaccine-related serious adverse events during the follow-up period. Evidence Rating Level: 1 (Excellent) Study Rundown: The risk of HPV-related
Cervical cancer is the second most common malignant cancer in women worldwide. It develops in the cervix, often due to Human Papilloma Virus (HPV) infections. Early identification via screenings, such as Pap and HPV tests, is vital for successful treatment.
1. In a meta-analysis of studies on provider-based interventions aimed at promoting human papillomavirus (HPV) vaccination, the rate of HPV vaccine initiation was 3.7% higher after the intervention. 2. Provider-based interventions were diverse, ranging from provider training to automated reminders, with heterogeneity in outcome measures between studies. Evidence Rating Level: 2 (Good) Study Rundown: Though vaccination